Clinical trial · Interventional
Outcomes Mandate National Integration With Cannabis as Medicine
NCT03944447CI-TRIAL-00058869OMNI-CanunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Conditions
Conditions (33)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Amyotrophic Lateral Sclerosis | — | UNRESOLVED | — |
| Anxiety | — | UNRESOLVED | — |
| Autism | — | UNRESOLVED | — |
| Bipolar Disorder | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chronic Pain | — | UNRESOLVED | — |
| Chronic Pain Due to Injury | — | UNRESOLVED | — |
| Chronic Pain Due to Trauma | — | UNRESOLVED | — |
| Chronic Pain Syndrome | — | UNRESOLVED | — |
| Chronic Traumatic Encephalopathy | — | UNRESOLVED | — |
| Coronavirus | — | UNRESOLVED | — |
| Corona Virus Infection | — | UNRESOLVED |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cannabis, Medical | Drug | — | UNRESOLVED |
| RYAH-Medtech Inhaler | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Cannabis users
- description
- Most patients will have used cannabis before their initial physician visit, and many current patients will be returning for an in-person follow-up. Patients will be given the survey shortly after the physician encounter to assess baseline parameters with current cannabis use. Any patient who is "cannabis-naïve", defined as no use within the past year or longer, will be placed into a separate data analysis arm. The investigators will follow up with patients again at 3, 6, 9, and 12 months with the online survey. Patients returning for their annual physician encounter will continue on the 3-month survey schedule until the end of the study, or if lost to follow-up. There may be slight variations in the interval based on state law, for example in Florida the in-person follow-up with the physician is required every 210 days, and some states allow for 2 year in-person visits. Every attempt will be made to adhere to a 3-month interval survey distribution.
- interventionNames
- Drug: Cannabis, Medical
- Device: RYAH-Medtech Inhaler
- type
- EXPERIMENTAL
- label
- Cancer prevention
- description
- Non-cancer patient medical cannabis users with extensive or life-long cannabis use will be compared to the general population for incidence and prevalence of development of cancer. The hypothesis is that cannabis use acts as a cancer preventive substance.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 7 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of a Qualifying Condition for Medical Marijuana * Must be 18 years or older unless they have consent from their parent or legal guardian as defined under state law parameters * Must be willing to complete online surveys at baseline and the follow up points in this study Exclusion Criteria: * Pregnancy * Breastfeeding * Inability to provide informed consent * Inability to complete study visits or questionnaires * Active suicidality or psychosis, that could be exacerbated by the administration of cannabis
References
Publications (0)
Data not yet available
No reference posted for this study.